This company listing is no longer active
Acerus Pharmaceuticals Management
Management criteria checks 2/4
Key information
Ed Gudaitis
Chief executive officer
US$807.1k
Total compensation
| CEO salary percentage | 24.7% |
| CEO tenure | 4.8yrs |
| CEO ownership | 1.0% |
| Management average tenure | 3.8yrs |
| Board average tenure | 6yrs |
Recent management updates
Have Insiders Been Buying Acerus Pharmaceuticals Corporation (TSE:ASP) Shares?
Mar 12
The Independent Director of Acerus Pharmaceuticals Corporation (TSE:ASP), Stephen Gregory, Just Bought 52% More Shares
Nov 30
Recent updates
Auditors Have Doubts About Acerus Pharmaceuticals (TSE:ASP)
Mar 14Have Insiders Been Buying Acerus Pharmaceuticals Corporation (TSE:ASP) Shares?
Mar 12Acerus Pharmaceuticals' (TSE:ASP) Shareholders Are Down 88% On Their Shares
Jan 22The Independent Director of Acerus Pharmaceuticals Corporation (TSE:ASP), Stephen Gregory, Just Bought 52% More Shares
Nov 30CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2022 | n/a | n/a | -US$28m |
| Jun 30 2022 | n/a | n/a | -US$29m |
| Mar 31 2022 | n/a | n/a | -US$28m |
| Dec 31 2021 | US$807k | US$199k | -US$34m |
| Sep 30 2021 | n/a | n/a | -US$32m |
| Jun 30 2021 | n/a | n/a | -US$34m |
| Mar 31 2021 | n/a | n/a | -US$33m |
| Dec 31 2020 | US$664k | US$177k | -US$24m |
| Sep 30 2020 | n/a | n/a | -US$21m |
| Jun 30 2020 | n/a | n/a | -US$19m |
| Mar 31 2020 | n/a | n/a | -US$16m |
| Dec 31 2019 | US$190k | US$181k | -US$16m |
| Sep 30 2019 | n/a | n/a | -US$17m |
| Jun 30 2019 | n/a | n/a | -US$16m |
| Mar 31 2019 | n/a | n/a | -US$19m |
| Dec 31 2018 | US$394k | US$185k | -US$19m |
Compensation vs Market: Ed's total compensation ($USD807.09K) is above average for companies of similar size in the Canadian market ($USD172.94K).
Compensation vs Earnings: Ed's compensation has increased whilst the company is unprofitable.
CEO
Ed Gudaitis
4.8yrs
Tenure
US$807,086
Compensation
Mr. Edward Gudaitis, also known as Ed, is President, Director and Chief Executive Officer at Acerus Pharmaceuticals Corp. since May 01, 2018. He is a Director for BioteCanada. Mr. Gudaitis has spent many y...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 4.8yrs | US$807.09k | 1.03% $ 28.6k | |
| Senior Vice President of International Commercial | 3.8yrs | US$411.98k | no data | |
| Chief Medical Officer | 2.7yrs | US$452.01k | no data | |
| Interim Chief Financial Officer | less than a year | no data | no data | |
| Investor Relations | no data | no data | no data | |
| Senior VP | 6.7yrs | US$287.97k | 0.0046% $ 128.8 | |
| President of Acerus Pharmaceuticals SRL | no data | US$306.94k | no data |
3.8yrs
Average Tenure
Experienced Management: ASP's management team is considered experienced (3.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 4.8yrs | US$807.09k | 1.03% $ 28.6k | |
| Vice Chairman | less than a year | no data | 0.032% $ 899.9 | |
| Chairman of the Board | 9.5yrs | US$46.15k | no data | |
| Independent Director | 11.7yrs | US$38.12k | no data | |
| Lead Independent Director | 7.3yrs | US$32.11k | 0.032% $ 877.4 | |
| Independent Director | 2.8yrs | US$44.01k | no data |
6.0yrs
Average Tenure
69yo
Average Age
Experienced Board: ASP's board of directors are considered experienced (6 years average tenure).